---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-037164"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T14:51:00.704772+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech enters ATM equity distribution agreement for up to $20M (current capacity $8.37M)

## Summary
- Up to $20M aggregate offering price; currently limited to ~$8.37M under S-3 rules.
- Canaccord receives 3% commission; shares sold at-the-market.
- Net proceeds for general corporate purposes including R&D and working capital.
- Agreement dated March 27, 2023; filed as Exhibit 1.1.

## SEC filing metadata
- accession: 0001104659-23-037164
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000110465923037164/0001104659-23-037164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000110465923037164/tm2310425d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-037164
- JSON: https://secwatch.observer/filing/0001104659-23-037164.json
- Plain text: https://secwatch.observer/filing/0001104659-23-037164.txt

## Key facts
- Material Agreements
  Edesa Biotech, Inc. entered into Equity Distribution Agreement with Canaccord Genuity LLC valued at up to $20.0 million (effective 2023-03-27).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Canaccord Genuity LLC
  - Value: up to $20.0 million
  - Effective: 2023-03-27
  source text: On March 27, 2023 Edesa Biotech, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Canaccord Genuity LLC (“Canaccord”), pursuant to which the Company may offer and sell from time to time, through Canaccord as sales agent and/or principal, common shares of the Company, no par value per share (the “Common Shares”), having an aggregate offering price of up to $20.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000110465923037164/0001104659-23-037164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.